News stories about Tobira Development (NASDAQ:TBRA) have trended somewhat positive on Friday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tobira Development earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.0801108500254 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/tobira-development-nasdaqtbra-given-daily-media-sentiment-rating-of-0-05/1472831.html.

About Tobira Development

Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.

Receive News & Ratings for Tobira Development Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.